195 related articles for article (PubMed ID: 34868349)
1. α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.
Melde M; Müller TM; Schneider I; Geppert CI; Mühl L; Besendorf L; Allner C; Becker E; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
Therap Adv Gastroenterol; 2021; 14():17562848211054707. PubMed ID: 34868349
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis.
Besendorf L; Müller TM; Geppert CI; Schneider I; Mühl L; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
Therap Adv Gastroenterol; 2022; 15():17562848221098899. PubMed ID: 35784193
[TBL] [Abstract][Full Text] [Related]
3. Expression of MAdCAM-1 and Gut-homing T Cells in Inflamed Pouch Mucosa.
de Krijger M; Wildenberg ME; Mookhoek A; Verheul S; de Jonge WJ; Ponsioen CY
J Crohns Colitis; 2021 Sep; 15(9):1491-1499. PubMed ID: 33675360
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
[TBL] [Abstract][Full Text] [Related]
5. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
6. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
[TBL] [Abstract][Full Text] [Related]
7. MAdCAM-1 Costimulates T Cells through Integrin α
DeBerg HA; Konecny AJ; Shows DM; Lord JD
Immunohorizons; 2022 Mar; 6(3):211-223. PubMed ID: 35273097
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab for chronic antibiotic-refractory pouchitis.
Singh A; Khan F; Lopez R; Shen B; Philpott J
Gastroenterol Rep (Oxf); 2019 Apr; 7(2):121-126. PubMed ID: 30976425
[TBL] [Abstract][Full Text] [Related]
9. Blocking GPR15 counteracts integrin-dependent T cell gut homing in vivo.
Schramm S; Liu LJ; Saad M; Dietz L; Dedden M; Müller TM; Atreya I; Voskens CJ; Atreya R; Neurath MF; Zundler S
J Crohns Colitis; 2024 Jan; ():. PubMed ID: 38243565
[TBL] [Abstract][Full Text] [Related]
10. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
11. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
[TBL] [Abstract][Full Text] [Related]
12. Residual homing of α4β7-expressing β1
Becker E; Dedden M; Gall C; Wiendl M; Ekici AB; Schulz-Kuhnt A; Schweda A; Voskens C; Hegazy A; Vitali F; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
Gut; 2022 Aug; 71(8):1551-1566. PubMed ID: 34462337
[TBL] [Abstract][Full Text] [Related]
13. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease.
Schneider I; Allner C; Mühl L; Melde M; Lissner D; Mantzivi E; Glauben R; Vitali F; Becker E; Atreya I; Müller TM; Atreya R; Siegmund B; Neurath MF; Zundler S
Transl Res; 2023 Mar; 253():8-15. PubMed ID: 36272713
[TBL] [Abstract][Full Text] [Related]
15. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
16. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.
Binder MT; Becker E; Wiendl M; Schleier L; Fuchs F; Leppkes M; Atreya R; Neufert C; Atreya I; Neurath MF; Zundler S
Inflamm Bowel Dis; 2018 May; 24(6):1237-1250. PubMed ID: 29788362
[TBL] [Abstract][Full Text] [Related]
17. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.
Bär F; Kühbacher T; Dietrich NA; Krause T; Stallmach A; Teich N; Schreiber S; Walldorf J; Schmelz R; Büning C; Fellermann K; Büning J; Helwig U;
Aliment Pharmacol Ther; 2018 Mar; 47(5):581-587. PubMed ID: 29266360
[TBL] [Abstract][Full Text] [Related]
19. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
[TBL] [Abstract][Full Text] [Related]
20. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
